Sanibel Captiva Trust Company Inc. Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

Sanibel Captiva Trust Company Inc. cut its stake in Danaher Co. (NYSE:DHR) by 4.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,354 shares of the conglomerate’s stock after selling 720 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Danaher were worth $3,754,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new position in Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $55,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 1.4 %

Shares of Danaher stock opened at $238.41 on Friday. The company has a 50-day moving average of $234.99 and a two-hundred day moving average of $253.37. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market cap of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the business posted $2.02 EPS. On average, research analysts anticipate that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. TD Cowen lifted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Raymond James dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Scotiabank initiated coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Finally, Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.